MXPA04004726A - Composiciones farmaceuticas en forma particulada. - Google Patents

Composiciones farmaceuticas en forma particulada.

Info

Publication number
MXPA04004726A
MXPA04004726A MXPA04004726A MXPA04004726A MXPA04004726A MX PA04004726 A MXPA04004726 A MX PA04004726A MX PA04004726 A MXPA04004726 A MX PA04004726A MX PA04004726 A MXPA04004726 A MX PA04004726A MX PA04004726 A MXPA04004726 A MX PA04004726A
Authority
MX
Mexico
Prior art keywords
produce
formulation
solid particles
drying
atomized
Prior art date
Application number
MXPA04004726A
Other languages
English (en)
Inventor
Ford Brandi
Original Assignee
Becton Dickinson Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton Dickinson Co filed Critical Becton Dickinson Co
Publication of MXPA04004726A publication Critical patent/MXPA04004726A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describe un metodo para preparar una composicion farmaceutica, que consiste en: (1) atomizar una formulacion liquida de un agente terapeutico para producir una formulacion atomizada; (2) congelar la formulacion atomizada para formar particulas solidas; y (3) secar las particulas solidas a aproximadamente la presion atmosferica para producir un polvo, en donde el secado se realiza en presencia de vibracion, elementos internos, agitacion mecanica, o una combinacion de estos. Se describe otro metodo, que consiste en : (1) atomizar una formulacion liquida de un agente terapeutico para producir una formulacion atomizada; (2) congelar la formulacion atomizada para formar particulas solidas; y (3) secar las particulas solidas para producir un polvo, en donde la formulacion atomizada comprende gotas que tienen un diametro promedio de entre aproximadamente 35 y aproximadamente 300 m [sic], y/o el polvo consiste en particulas secas que tienen un diametro promedio de entre aproximadamente 35 m y aproximadamente 300 m [sic]. Tambien se describen las composiciones elaboradas por los metodos anteriores, y los metodos para utilizar las composiciones.
MXPA04004726A 2001-11-19 2002-11-19 Composiciones farmaceuticas en forma particulada. MXPA04004726A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33195201P 2001-11-19 2001-11-19
US33915601P 2001-12-11 2001-12-11
US41995902P 2002-10-22 2002-10-22
PCT/US2002/036882 WO2003072016A2 (en) 2001-11-19 2002-11-19 Pharmaceutical compositions in particulate form

Publications (1)

Publication Number Publication Date
MXPA04004726A true MXPA04004726A (es) 2004-07-30

Family

ID=27406830

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA04004730A MXPA04004730A (es) 2001-11-19 2002-11-19 Composiciones farmaceuticas en forma particulada.
MXPA04004726A MXPA04004726A (es) 2001-11-19 2002-11-19 Composiciones farmaceuticas en forma particulada.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MXPA04004730A MXPA04004730A (es) 2001-11-19 2002-11-19 Composiciones farmaceuticas en forma particulada.

Country Status (11)

Country Link
US (3) US7842310B2 (es)
EP (2) EP1455754A4 (es)
JP (2) JP2005518430A (es)
KR (2) KR20040073438A (es)
CN (2) CN1287770C (es)
AU (2) AU2002346424A1 (es)
BR (2) BR0214279A (es)
CA (2) CA2466982A1 (es)
MX (2) MXPA04004730A (es)
WO (2) WO2003072016A2 (es)
ZA (1) ZA200403848B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
KR20040073438A (ko) * 2001-11-19 2004-08-19 벡톤 디킨슨 앤드 컴퍼니 입자 형태의 약제학적 조성물
AU2003230908A1 (en) * 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
EP1592443B1 (en) * 2003-02-13 2011-03-30 Becton, Dickinson and Company Improved anthrax vaccines and delivery methods
WO2004073652A2 (en) * 2003-02-20 2004-09-02 Becton Dickinson And Company Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
US20040209361A1 (en) * 2003-04-18 2004-10-21 Hemperly John J. UV-cross-linked PVA-based polymer particles for cell culture
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
CA2435632A1 (en) * 2003-07-21 2005-01-21 Warren Hugh Finlay Formulation of powder containing nanoparticles for aerosol delivery to the lung
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
JP2007534633A (ja) * 2003-11-10 2007-11-29 アライバ−プロメティック インコーポレイティド ヒト・アルファ１−抗トリプシン製剤
US7007406B2 (en) * 2004-01-23 2006-03-07 Zhaolin Wang Powder formation by atmospheric spray-freeze drying
EP1697035B1 (en) * 2003-12-22 2017-11-15 Warren H. Finlay Powder formation by atmospheric spray-freeze drying
BRPI0509493A (pt) * 2004-04-01 2007-09-11 Alza Corp aparelho e método para a liberação transdérmica de vacina da influenza
EP1794524B1 (en) * 2004-07-23 2012-01-18 Bayer Technology Services GmbH Sterile freezing, drying, storing, assaying and filling process (sfd-saf process) (pellet freeze-drying process for parenteral biopharmaceuticals)
JP2009514902A (ja) * 2005-11-11 2009-04-09 バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー． 凝集ナノ粒子を含む固体医薬組成物及びその生成方法
US8097245B2 (en) 2005-12-28 2012-01-17 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
GB0614460D0 (en) * 2006-07-20 2006-08-30 Novartis Ag Vaccines
US20080075777A1 (en) * 2006-07-31 2008-03-27 Kennedy Michael T Apparatus and methods for preparing solid particles
EP2068834A2 (en) * 2006-09-08 2009-06-17 Becton, Dickinson & Company Stable powder formulations of aluma-dsorbed vaccines
EP1915987A1 (en) * 2006-10-27 2008-04-30 MediGene AG Spray-freeze-drying process for the preparation of pellets comprising percolation drying
US20100285040A1 (en) * 2006-11-17 2010-11-11 Iacob Mathiesen Methods of enhancing immune response using electroporation-assisted vaccination and boosting
CA2673120C (en) 2006-12-18 2012-08-07 Advanced Bionutrition Corporation A dry food product containing live probiotic
EP1972347A1 (en) 2007-03-19 2008-09-24 Becton, Dickinson and Company, Wagner, Jaconda Stable vaccine powder formulations
GB0707612D0 (en) * 2007-04-19 2007-05-30 Stratosphere Pharma Ab Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
TWI436789B (zh) * 2008-01-21 2014-05-11 Intervet Int Bv 含有藥學化合物的顆粒之冷凍乾燥方法及含有此顆粒的藥學包
WO2010111565A2 (en) 2009-03-27 2010-09-30 Advanced Bionutrition Corporation Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
JP5804453B2 (ja) * 2009-05-14 2015-11-04 国立大学法人 東京大学 結晶性ポリオール微粒子及びその調製方法
PL2435554T3 (pl) 2009-05-26 2018-01-31 Advanced Bionutrition Corp Stabilna kompozycja suchego proszku zawierająca biologicznie aktywne mikroorganizmy i/lub materiały bioaktywne i sposoby jej wykonania
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
AR080073A1 (es) 2010-01-28 2012-03-14 Advanced Bionutrition Corp Composicion vitrea seca que comprende un material bioactivo
JP5771626B2 (ja) 2010-04-15 2015-09-02 株式会社新日本科学 鼻内送達のための方法および組成物
JP5996837B2 (ja) * 2010-05-28 2016-09-21 小林製薬株式会社 インフルエンザウイルスの感染抑制剤
ES2649045T3 (es) 2010-08-04 2018-01-09 Ima Life North America Inc. Liofilización a granel mediante congelación por pulverización y secado agitado
US9945611B2 (en) 2010-08-04 2018-04-17 Ima Life North America Inc. Bulk freeze drying using spray freezing and agitated drying
BR112013003244B1 (pt) 2010-08-13 2018-07-17 Advanced Bionutrition Corp composição seca estabilizante para material biológico, seu método de preparação, e formulação de carreamento oral
CN103347535B (zh) 2010-12-02 2015-11-25 昂科利蒂克斯生物科技公司 液体病毒制剂
MX349294B (es) 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
US9446209B2 (en) 2011-09-07 2016-09-20 Concentrx Pharmaceuticals, Inc. Dry powder inhalation device
EP2578974A1 (en) 2011-10-05 2013-04-10 Sanofi Pasteur Sa Process line for the production of freeze-dried particles
US8956566B2 (en) 2012-03-12 2015-02-17 Pure Biosolutions, Llc System and method for virus inactivation
EP2671591B1 (en) * 2012-06-08 2017-08-09 Corden Pharma Brussels Process for the preparation of short-chain peptide powders
CN102830222B (zh) * 2012-09-20 2014-11-26 成都斯马特科技有限公司 一种固体颗粒状生化试剂的制备方法
KR102358369B1 (ko) 2013-12-19 2022-02-03 에어로졸 세라퓨틱스 엘엘씨 대기 분무 동결 건조를 위한 조성물 및 방법
CN104198717B (zh) * 2014-08-30 2016-04-06 中国科学院苏州生物医学工程技术研究所 一种浓缩葡萄糖检测试剂冻干微球及其制备方法
JP5837670B2 (ja) * 2014-10-24 2015-12-24 アイエムエー ライフ ノース アメリカ インコーポレーテッド 噴霧凍結および撹拌乾燥を使用するバルク・フリーズドライ
CA2967039A1 (en) * 2014-11-10 2016-05-19 National Institutes Of Health Probiotic therapeutic applications
EP3283125B1 (en) 2015-04-17 2021-12-29 CureVac Real Estate GmbH Lyophilization of rna
WO2016184575A1 (en) 2015-05-20 2016-11-24 Curevac Ag Dry powder composition comprising long-chain rna
EP3928800A3 (en) 2015-05-20 2022-03-23 CureVac AG Dry powder composition comprising long-chain rna
JP6889699B2 (ja) 2015-07-29 2021-06-18 アドバンスド バイオニュートリション コープ． 特定栄養用途のための安定乾燥プロバイオティクス組成物
AU2016317661B2 (en) * 2015-08-28 2023-05-18 Ology Bioservices, Inc. Norovirus vaccine
TWI590817B (zh) 2015-10-14 2017-07-11 鈺邦科技股份有限公司 含浸設備及含浸方法
CN110087718A (zh) * 2016-12-13 2019-08-02 库尔诊疗公司 肺部***中的密相材料运输
CN106889058B (zh) * 2017-02-20 2019-07-19 徐小杨 一种细胞冻干***和方法
EP3600504B1 (en) 2017-03-28 2023-07-12 Concentrx Pharmaceuticals, Inc. Device for delivering dry powder medicaments
WO2019021957A1 (ja) * 2017-07-25 2019-01-31 第一三共株式会社 点鼻用乾燥粉末医薬組成物
CN107875407A (zh) * 2017-12-15 2018-04-06 天津梅花生物医药科技有限公司 一种新型的原料药无菌处理***
IT201900023046A1 (it) * 2019-12-05 2021-06-05 Vomm Impianti E Processi S P A Prodotto in forma di polvere comprendente lattosio e suo procedimento di produzione
CN111269444A (zh) * 2020-01-22 2020-06-12 苏州新丝原生物科技有限公司 一种交联微球及其制备方法和应用
WO2021211624A1 (en) * 2020-04-14 2021-10-21 Qool Therapeutics, Inc. Frozen particle generator using liquid micro-dispenser
CA3173146C (en) 2020-11-16 2023-10-31 Joel Peter LENNON-MEYER Continuous throughput lyophilizer/powder filler within a sterile boundary
CN112484396A (zh) * 2020-12-29 2021-03-12 南通联源机电科技股份有限公司 一种用于精品砂干燥除泥用的振动流化床
CN114272372A (zh) * 2021-12-28 2022-04-05 方坦思(上海)生物医药有限公司 一种单克隆抗体冻干粉制剂及其制备工艺
WO2023138670A1 (en) * 2022-01-21 2023-07-27 The University Of Hong Kong Dual targeting powder formulation of antiviral agent for nasal and lung deposition through single intranasal administration

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US656871A (en) * 1898-03-11 1900-08-28 Walter Rushton Under screen for carding-engines.
US656888A (en) * 1899-09-30 1900-08-28 Winfield S Haines Engine-valve.
US2798835A (en) * 1954-01-18 1957-07-09 American Cyanamid Co Newcastle disease and infectious bronchitis vaccines and production thereof
US2946724A (en) 1957-05-29 1960-07-26 American Cyanamid Co Stable poliomyelitis live virus vaccine
US3313032A (en) * 1966-07-28 1967-04-11 George J Malecki Freeze-drying process and apparatus
US3957965A (en) * 1967-08-08 1976-05-18 Fisons Limited Sodium chromoglycate inhalation medicament
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1163470A (en) * 1967-11-13 1969-09-04 Cecil Arthur Clark Improvements in or relating to Adjuvant Vaccines
DK126720B (da) * 1968-05-11 1973-08-13 Leybold Heraeus Verwaltung Apparat til kontinuerlig frysettørring.
FR7461M (es) 1968-06-19 1970-01-05
US3932943A (en) 1970-08-14 1976-01-20 E. I. Du Pont De Nemours And Company Method of preparation of lyophilized biological products
NL7012832A (es) 1970-08-29 1972-03-02
FR2299011A1 (fr) 1975-01-29 1976-08-27 Obert Jean Claude Generateur d'aerosols de part
US4323478A (en) 1977-01-18 1982-04-06 Baxter Travenol Laboratories, Inc. Novel particulate compositions
US4329332A (en) 1978-07-19 1982-05-11 Patrick Couvreur Biodegradable submicroscopic particles containing a biologically active substance and compositions containing them
US4251509A (en) 1980-01-31 1981-02-17 Wisconsin Alumni Research Foundation Dry particulate vaccine for oral administration
EP0058021A3 (en) * 1981-02-06 1982-10-27 Beecham Group Plc Pharmaceutical compositions
JPS59163313A (ja) 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
CH664005A5 (de) * 1984-05-19 1988-01-29 Glatt Maschinen & Apparatebau Verfahren zum trocknen eines teilchenfoermigen gutes und einrichtung zur durchfuehrung des verfahrens.
JPS61194034A (ja) 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5690954A (en) 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
DE3886880T2 (de) * 1987-10-15 1994-07-14 Syntex Inc Pulverförmige Zubereitungen zur intranasalen Verabreichung von Polypeptiden.
JPH0739339B2 (ja) * 1989-05-01 1995-05-01 アルカーメス コントロールド セラピューティクス，インコーポレイテッド 生物活性を有する分子の小粒子の製造方法
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
NL9000207A (es) 1990-01-29 1991-08-16 Duphar Int Res
US5208998A (en) 1991-02-25 1993-05-11 Oyler Jr James R Liquid substances freeze-drying systems and methods
DE69306755T2 (de) 1992-01-21 1997-04-10 Stanford Res Inst Int Verbessertes verfahren zur herstellung von mikronisierter polypeptidarzneimitteln
GB9209118D0 (en) * 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
US6290962B1 (en) 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
TW360548B (en) * 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
GB9316745D0 (en) * 1993-08-12 1993-09-29 Medeva Holdings Bv Vaccine compositions
JPH07112940A (ja) * 1993-08-26 1995-05-02 Takeda Chem Ind Ltd 徐放性非経口投与製剤およびその製造方法
EP0725653B2 (en) 1993-10-05 2008-04-02 UCB Pharma Limited Vaccine compositions
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
ES2316917T3 (es) 1994-03-07 2009-04-16 Nektar Therapeutics Metodos y composiciones para suministro pulmonar de insulina.
WO1995031479A1 (en) 1994-05-18 1995-11-23 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
SE9404468D0 (sv) 1994-12-22 1994-12-22 Astra Ab Powder formulations
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
CA2230494A1 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
GB9522351D0 (en) 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
DE69608122T3 (de) * 1995-11-09 2011-06-16 Microbiological Research Authority Camr, Salisbury Mikroverkapselte dna zur impfung und gentherapie
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
USRE37053E1 (en) * 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5908825A (en) * 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
US20030096259A1 (en) * 1999-08-24 2003-05-22 Medlmmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs), homogeneous VLP and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
US6554497B2 (en) * 1998-01-28 2003-04-29 Fuji Photo Film Co., Ltd. Compact camera
US6328967B1 (en) * 1998-03-12 2001-12-11 Allergenics, Inc. Delivery system to modulate immune response
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
GB9810126D0 (es) * 1998-05-13 1998-07-08 Glaxo Group Ltd
WO2000014547A1 (en) 1998-09-04 2000-03-16 Powderject Research Limited Immunodiagnostics using particle delivery methods
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
IL144597A0 (en) 1999-02-03 2002-05-23 Powderject Res Ltd Hydrogel particle formulations
AU4979700A (en) 1999-05-03 2000-11-17 Battelle Memorial Institute Compositions for aerosolization and inhalation
GB9916316D0 (en) * 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
WO2001052818A1 (en) 2000-01-19 2001-07-26 Pharmaceutical Discovery Corporation Dry powder formulations of antihistamine for nasal administration
EP1118331A1 (en) * 2000-01-21 2001-07-25 I.D.M. Immuno-Designed Molecules Method for enhancing the presentation of exogenous antigen by human antigen-presenting cells and opsonized micro particle complexes for applying this method
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
AU2001238478C1 (en) 2000-02-15 2006-11-09 Id Biomedical Corporation Of Quebec Proteosome influenza vaccine
US20020009463A1 (en) * 2000-02-23 2002-01-24 Jan Raa Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
US6584782B2 (en) 2000-02-25 2003-07-01 Glatt Gmbh Method for producing particulate goods
GB0004827D0 (en) * 2000-02-29 2000-04-19 Quadrant Holdings Cambridge Compositions
US20020120228A1 (en) * 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
NZ552576A (en) * 2000-06-08 2008-06-30 Powderject Vaccines Inc Salt adjuvant-containing gel-forming free flowing compositions in a powder form for transdermal delivery from a needless syringe
CN1446077A (zh) * 2000-08-07 2003-10-01 耐科塔医药公司 具有最小聚集的可吸入喷雾干燥4－螺旋束蛋白粉剂
US6565888B1 (en) * 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
US20020128179A1 (en) 2000-12-01 2002-09-12 Tacon William C. Shaped microparticles for pulmonary drug delivery
US20020159954A1 (en) 2000-12-01 2002-10-31 Parker Small Aerodynamically light vaccine for active pulmonary immunization
EP1345629A2 (en) * 2000-12-29 2003-09-24 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
CA2436418A1 (en) 2001-01-30 2002-08-08 Board Of Regents, The University Of Texas Systems Process for production of nanoparticles and microparticles by spray freezing into liquid
US6596262B2 (en) * 2001-02-15 2003-07-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6485707B2 (en) 2001-02-15 2002-11-26 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6544497B2 (en) 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6551578B2 (en) 2001-02-15 2003-04-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US20030051728A1 (en) * 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US20030009149A1 (en) * 2001-06-08 2003-01-09 Yasmin Thanavala Method for nasal application of a medicinal substance
US6537265B2 (en) 2001-06-08 2003-03-25 Health Research, Inc. Method for nasal application of a medicinal substance
EP1399131A2 (en) * 2001-06-08 2004-03-24 Powderject Vaccines, Inc. Spray freeze-dried compositions
DK1418890T3 (da) 2001-08-16 2008-08-11 Baxter Int Drivmiddel-baserede mikropartikelformuleringer
US20030044771A1 (en) 2001-08-30 2003-03-06 Anderson Norman G. Method for discovering new infectious particles
CA2492826C (en) 2001-09-14 2016-12-13 Cytos Biotechnology Ag Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
US20030091592A1 (en) * 2001-10-09 2003-05-15 Barber Glen N. Generation of virus-like particles by VSV
KR20040073438A (ko) * 2001-11-19 2004-08-19 벡톤 디킨슨 앤드 컴퍼니 입자 형태의 약제학적 조성물
CA2465675C (en) * 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Improved particulate compositions for pulmonary delivery
AU2003230908A1 (en) * 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
WO2003105780A2 (en) * 2002-06-18 2003-12-24 Epigenesis Pharmaceuticals, Inc. A dry powder oligonucleotide formulation, preparation and its uses
WO2004073652A2 (en) * 2003-02-20 2004-09-02 Becton Dickinson And Company Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
US7007406B2 (en) * 2004-01-23 2006-03-07 Zhaolin Wang Powder formation by atmospheric spray-freeze drying

Also Published As

Publication number Publication date
JP2005518430A (ja) 2005-06-23
AU2002366267A1 (en) 2003-09-09
JP2005532987A (ja) 2005-11-04
BR0214279A (pt) 2005-12-20
CA2466982A1 (en) 2003-05-30
US20070190158A1 (en) 2007-08-16
US20030180755A1 (en) 2003-09-25
WO2003072016A2 (en) 2003-09-04
AU2002366267B2 (en) 2007-05-10
EP1455754A2 (en) 2004-09-15
WO2003072016A3 (en) 2003-11-20
CN1607941A (zh) 2005-04-20
US20030186271A1 (en) 2003-10-02
MXPA04004730A (es) 2004-07-30
US7842310B2 (en) 2010-11-30
EP1458362A2 (en) 2004-09-22
KR20050044523A (ko) 2005-05-12
KR20040073438A (ko) 2004-08-19
CN1607942A (zh) 2005-04-20
WO2003043574A3 (en) 2004-03-04
EP1455754A4 (en) 2006-01-18
BR0214280A (pt) 2005-01-11
AU2002346424A1 (en) 2003-06-10
CN1287770C (zh) 2006-12-06
WO2003043574A2 (en) 2003-05-30
EP1458362A4 (en) 2006-01-18
ZA200403848B (en) 2005-07-27
CA2467833A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
MXPA04004726A (es) Composiciones farmaceuticas en forma particulada.
DK1214058T3 (da) Fremgangsmåde til opnåelse af mikorpartikler
WO2002101412A3 (en) Spray freeze-dried compositions
LV12231A (lv) Dispersa makromolekulu kompozicija
HUP0202062A2 (hu) Eljárás maszkírozott ízű és azonnali hatóanyag-leadású bevont szemcsék előállítására
CA2508870A1 (en) Prefilming atomizer
AP1861A (en) Dry powder inhalation system for transpulmonary administration
BR9909394A (pt) Composição de aerossol, composição farmacêutica, recipiente, dispositivo de inalação, processo para preparar uma composição de aerossol, mistura de um primeiro material particulado, e, processo para administrar um medicamento particulado
AU2003291973A1 (en) A self-cleaning spray nozzle
CA2352627A1 (en) Effervescence components
SE9700135D0 (sv) New formulation
KR880000597A (ko) 바이오폴리머 입자 및 그의 제법
CA2268626A1 (en) Pharmaceutical composition for rapid suspension in aqueous media
PL343342A1 (en) Particulate active agent support for pulmonary application
NZ506241A (en) Solid cyclodextrin flavor delivery systems
CA2336570A1 (en) Croscarmellose taste masking
JPS61280428A (ja) 潤滑性を有する水溶性ビタミン粉末の製法
ID22883A (id) Formulasi untuk inhalasi yang memiliki densitas ruah terlimpah antara 0,28 sampai 038 g/ml dan mengandung budesonida
WO2004073652A3 (en) Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
DE69907717D1 (de) Pharmazeutische formulierung in form eines trockenen pulvers
CA2390107A1 (en) Storage-stable aerated gel composition and a process for producing it
NZ236631A (en) Process for the preparation of a spray dried powdered pharmaceutical formulation of naproxen
ES257336A1 (es) Metodo para la producciën de una preparaciën seca pulverulenta
AP2000001837A0 (en) Pharmaceutical compositions containing micronized bicyclic drugs.
JPS6143389B2 (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal